MX2014005620A - Proteínas de fusión propéptido-luciferasa y método de uso de las mismas. - Google Patents

Proteínas de fusión propéptido-luciferasa y método de uso de las mismas.

Info

Publication number
MX2014005620A
MX2014005620A MX2014005620A MX2014005620A MX2014005620A MX 2014005620 A MX2014005620 A MX 2014005620A MX 2014005620 A MX2014005620 A MX 2014005620A MX 2014005620 A MX2014005620 A MX 2014005620A MX 2014005620 A MX2014005620 A MX 2014005620A
Authority
MX
Mexico
Prior art keywords
propeptide
methods
fusion proteins
luciferase fusion
protein
Prior art date
Application number
MX2014005620A
Other languages
English (en)
Other versions
MX361861B (es
Inventor
Sean Burns
David Altshuler
Amedeo Vetere
Original Assignee
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Inst Inc filed Critical Broad Inst Inc
Publication of MX2014005620A publication Critical patent/MX2014005620A/es
Publication of MX361861B publication Critical patent/MX361861B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona construcciones de ácido nucleico que codifican péptidos de fusión que comprenden una proteína bioluminiscente y un precursor de un péptido secretado o proteína expresada en la superficie celular y ensayos de cribado de alto rendimiento usando los mismos.
MX2014005620A 2011-11-07 2012-11-07 Proteínas de fusión propéptido-luciferasa y método de uso de las mismas. MX361861B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161556619P 2011-11-07 2011-11-07
US201161576530P 2011-12-16 2011-12-16
PCT/US2012/063982 WO2013070796A2 (en) 2011-11-07 2012-11-07 Propeptide-luciferase fusion proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2014005620A true MX2014005620A (es) 2015-02-12
MX361861B MX361861B (es) 2018-12-18

Family

ID=47215793

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005620A MX361861B (es) 2011-11-07 2012-11-07 Proteínas de fusión propéptido-luciferasa y método de uso de las mismas.

Country Status (4)

Country Link
US (2) US9657329B2 (es)
EP (1) EP2776579B1 (es)
MX (1) MX361861B (es)
WO (1) WO2013070796A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190060016A (ko) * 2014-10-20 2019-05-31 뉴럴스템, 인크. 성장 인자를 코딩하는 외인성 폴리뉴클레오티드를 포함하는 안정한 신경 줄기세포 및 그의 사용 방법
US20180340208A1 (en) * 2015-10-15 2018-11-29 Woods Hole Oceanographic Institution Compositions and methods for absolute quantification of proteins
WO2018069442A1 (en) 2016-10-12 2018-04-19 University Of Copenhagen Peptide dual agonists of gipr and glp2r
EP3601326A4 (en) 2017-03-20 2020-12-16 The Broad Institute, Inc. COMPOUNDS AND METHODS OF REGULATING INSULIN SECRETION
CN108314723A (zh) * 2018-01-11 2018-07-24 温州医科大学 一种人源突变型神经生长因子及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5139749A (en) 1990-06-22 1992-08-18 Tas, Inc. Fluidized calcining process
DK0705279T3 (da) 1993-05-27 2003-06-10 Selectide Corp Topologisk adskilte, kodende fastfase-biblioteker
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
WO2003016839A2 (en) 2001-08-15 2003-02-27 Xenogen Corporation Modified railroad worm red luciferase coding sequences
JP5572972B2 (ja) * 2009-03-16 2014-08-20 Ｊｎｃ株式会社 インスリン分泌促進剤などの薬物のスクリーニング方法
JP5764921B2 (ja) * 2009-12-24 2015-08-19 Jnc株式会社 発光活性を有する融合蛋白質
US20130243741A1 (en) * 2010-09-21 2013-09-19 Kansas State University Research Foundation Renilla/gaussia transfected cells as a light source for in-situ photodynamic therapy of cancer

Also Published As

Publication number Publication date
WO2013070796A3 (en) 2013-09-12
US20170260565A1 (en) 2017-09-14
EP2776579B1 (en) 2019-05-01
US10370697B2 (en) 2019-08-06
US9657329B2 (en) 2017-05-23
WO2013070796A2 (en) 2013-05-16
EP2776579A2 (en) 2014-09-17
MX361861B (es) 2018-12-18
US20140303035A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
EA201171148A1 (ru) Антитело-антагонист, специфичное для гетеродимера альфа-4-бета-7
WO2013142859A3 (en) Fusion proteins of superfolder green fluorescent protein and use thereof
WO2012139110A3 (en) Peptide constructs and assay systems
IL276469A (en) Non-viral DNA vectors and their uses for the production of antibody and fusion protein
MX2018013738A (es) Anticuerpos que comprenden dominios constantes quimericos.
EP2534257A4 (en) METHOD OF IDENTIFYING AND ISOLATING CELLS FOR THE EXPRESSION OF POLYPEPTIDES
MX2021010925A (es) Metodos y composiciones para la expresion genica en plantas.
MX360741B (es) Constructos de polipéptidos y sus usos.
MX2014005620A (es) Proteínas de fusión propéptido-luciferasa y método de uso de las mismas.
NZ596735A (en) Recombinant production of peptides
IL222507A0 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
SG11201601262QA (en) CELL CULTURE MEDIUM AND PROCESS FOR CONTROLLING α-AMIDATION AND/OR C-TERMINAL AMINO ACID CLEAVAGE OF POLYPEPTIDES
PH12015500107A1 (en) Process for designing diverged, condon-optimized large repeated dna sequences
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
PL3461888T3 (pl) Ulegające zużyciu krioprezerwowane komórki wykazujące przejściową nadekspresję genu(-ów) kodującego(-ych) białko(-a) transportera leku i/lub enzym(y) metabolizujący(-e) lek
EP3186272A4 (en) Functionalized beta-sheet peptide stabilized membrane proteins, constructs comprising same, and methods of forming and using same
EP2281003A4 (en) HUMANIZED ANTIBODIES TO THE AMINO ACID SEQUENCE RGD OF EXTRACELLULAR MATRIX PROTEIN AND ITS USE
EP2480665A4 (en) HUMANIZED ANTIBODIES TO THE AMINO ACID SEQUENCE RGD OF EXTRACELLULAR MATRIX PROTEIN AND ITS USE
WO2008138001A3 (en) Synthetic peptides and peptide mimetics
MX2016006586A (es) Identificacion de una citocina de linfocitos b novedosa.
ZA201307784B (en) Anti-cyanobacteria recombinant antibody polypeptide gene therefor and prepration method thereof
BR112015012649A2 (pt) agonista de ron, composição farmacêutica, métodos, proteína de fusão msp, moléculas de ácido nucleico isoladas, vetores, células hospedeiras e anticorpos isolados.
NZ750009A (en) Antibodies comprising chimeric constant domains
UA104311C2 (ru) Антитело-антагонист, специфическое для гетеродимера альфа-4-бета-7
WO2011156694A3 (en) Enrichment and purification of infectious prion proteins

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: PHARMACYCLICS LLC

GB Transfer or rights

Owner name: THE BROAD INSTITUTE, INC.

FG Grant or registration